14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions

Example Citation: 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.

Active as of 2023-12-17

Generated Narrative: Citation

Resource Citation "179628" Version "1" Updated "2023-11-26 22:35:27+0000"

StructureDefinition Work Group: cds

url: https://fevir.net/resources/Citation/179628

identifier: FEvIR Object Identifier: 179628, id: 14706014

version: 1.0.0-ballot

title: 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.

status: active

date: 2023-12-17 16:55:23+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

Code

Value[x]

FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')

Medline Base (Citation Artifact Classifier#medline-base)

jurisdiction: World (m49.htm#001)

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2004-06-15

lastReviewDate: 2019-09-22

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification
type: Citation Source (Citation Classification Type#citation-source)
classifier: MEDLINE ()

classification
type: MEDLINE Citation Owner (Citation Classification Type#medline-owner)
classifier: National Library of Medicine, Index Section (elements_descriptions.html#owner_value#NLM)

currentState: Medline Citation Status of Medline (Citation Status Type#medline-medline), PubMed PublicationStatus of ppublish (Citation Status Type#pubmed-publication-status-ppublish)

statusDate
activity: PubMed Pubstatus of Pubmed (Citation Status Type#pubmed-pubstatus-pubmed)
period: ?? --> 2004-01-07 05:00:00+0000

statusDate
activity: PubMed Pubstatus of Medline (Citation Status Type#pubmed-pubstatus-medline)
period: ?? --> 2004-06-16 05:00:00+0000

statusDate
activity: PubMed Pubstatus of Entrez (Citation Status Type#pubmed-pubstatus-entrez)
period: ?? --> 2004-01-07 05:00:00+0000

citedArtifact
identifier: id: 14706014, id: 10.1111/j.1442-2042.2004.t01-1-00748.x, pii: 748
Titles
- Type Language Text
* Primary title (Title Type#primary) English (Tags for the Identification of Languages#en) Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
Abstracts
- Text
* **BACKGROUND:** The present study was undertaken mainly to investigate whether chemohormonal therapy with estramustine phosphate plus luteinizing hormone-releasing hormone (LHRH) agonist has a more beneficial effect than the hormonal therapy with flutamide plus LHRH agonist for newly diagnosed patients with metastatic prostate cancer. **METHODS:** A total of 57 patients with metastatic prostate cancer aged 59-80 years (median 74 years) were entered in the study and were randomized to the treatment of estramustine phosphate (560 mg/day) plus LHRH agonist (estramustine group) or flutamide (375 mg/day) plus LHRH agonist (flutamide group) with stratification for the degree of performance status, histological differentiation and bone metastasis. **RESULTS:** Both of the treatment regimens were well tolerated with similar incidences of adverse drug reactions. The overall response rates (complete response plus partial response) at 12 weeks after treatment in the estramustine and flutamide groups were 76 and 55%, respectively. The median time to objective progression for the estramustine group (25.4 months) was longer than that of the flutamide group (14.6 months). The serum levels of follicle stimulating hormone and testosterone were significantly lower in the estramustine group. **CONCLUSIONS:** Chemohormonal therapy with estramustine phosphate plus LHRH agonist showed longer clinical progression-free survival than the hormonal therapy with flutamide plus LHRH agonist (P = 0.03), although there was no significant difference in the overall survival. A larger-scaled trial with more statistical power is required to clarify that the former regimen is more beneficial than the latter for newly diagnosed patients with advanced prostate cancer.
publicationForm
PublishedIns
- Type Identifier Title PublisherLocation
* Periodical (Published In Type#D020492) Print ISSN Type: 0919-8172, ISOAbbreviation: Int J Urol, ISSN Linking: 0919-8172, Medline Title Abbreviation: Int J Urol, NLM Unique ID: 9440237 International journal of urology : official journal of the Japanese Urological Association Australia
citedMedium: Print (Cited Medium#print)
volume: 11
issue: 2
articleDate: 2004-02
publicationDateText: 2004-Feb
language: English (Tags for the Identification of Languages#en)
pageString: 103-9
WebLocations
- Classifier Url
* Abstract (Artifact Url Classifier#abstract) https://pubmed.ncbi.nlm.nih.gov/14706014/
classification
type: Publishing Model (Cited Artifact Classification Type#publishing-model)
classifier: Print (Citation Artifact Classifier#Print)
classification
type: Chemical (Cited Artifact Classification Type#chemical)
classifier: Androgen Antagonists (#D000726), Antineoplastic Agents, Hormonal (#D018931), Gonadotropin-Releasing Hormone (chemical-substances#33515-09-2; #D007987), Estramustine (chemical-substances#35LT29625A; #D004961), Flutamide (chemical-substances#76W6J0943E; #D005485)
classification
type: MeSH Heading (Cited Artifact Classification Type#mesh-heading)
artifactAssessment:

artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged (#D000368)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged, 80 and over (#D000369)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Agents, Hormonal (#D018931)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Disease-Free Survival (#D018572)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Dose-Response Relationship, Drug (#D004305)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Drug Administration Schedule (#D004334)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Drug Therapy, Combination (#D004359)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Estramustine (#D004961)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Flutamide (#D005485)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Gonadotropin-Releasing Hormone (#D007987)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: antagonists & inhibitors (#Q000037)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Middle Aged (#D008875)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Neoplasm Invasiveness (#D009361)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Neoplasm Staging (#D009367)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Probability (#D011336)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prognosis (#D011379)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Survival Analysis (#D016019)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Treatment Outcome (#D016896)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
classification
type: Publication Type (Cited Artifact Classification Type#publication-type)
classifier: Clinical Trial (#D016430), Journal Article (#D016428), Randomized Controlled Trial (#D016449)
classification
type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)
classifier: Journal Article (Citation Artifact Classifier#D016428)
artifactAssessment: : Classifier added by Computable Publishing LLC
classification
type: Citation Subset (Cited Artifact Classification Type#citation-subset)
classifier: IM (elements_descriptions.html#citationsubset#IM)
contributorship
complete: true
entry
contributor:

name: Masanori Noguchi
forenameInitials: M
affiliation: : Department of Urology, Kurume University School of Medicine, Kurume, Japan. noguchi@med.kurume-u.ac.jp
entry
contributor:

name: Shinshi Noda
forenameInitials: S
entry
contributor:

name: Masaki Yoshida
forenameInitials: M
entry
contributor:

name: Shoichi Ueda
forenameInitials: S
entry
contributor:

name: Taizo Shiraishi
forenameInitials: T
entry
contributor:

name: Kyogo Itoh
forenameInitials: K
entry
contributor:

name: Kurume-Kumamoto Estracyt Study Group

Generated Narrative: Practitioner #author0
name: Masanori Noguchi

Generated Narrative: Practitioner #author1
name: Shinshi Noda

Generated Narrative: Practitioner #author2
name: Masaki Yoshida

Generated Narrative: Practitioner #author3
name: Shoichi Ueda

Generated Narrative: Practitioner #author4
name: Taizo Shiraishi

Generated Narrative: Practitioner #author5
name: Kyogo Itoh

Generated Narrative: Organization #author6
name: Kurume-Kumamoto Estracyt Study Group

Generated Narrative: ArtifactAssessment #meshHeading0
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged (#D000368)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged, 80 and over (#D000369)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Agents, Hormonal (#D018931)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Disease-Free Survival (#D018572)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Dose-Response Relationship, Drug (#D004305)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Drug Administration Schedule (#D004334)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Drug Therapy, Combination (#D004359)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Estramustine (#D004961)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Flutamide (#D005485)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Gonadotropin-Releasing Hormone (#D007987)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: antagonists & inhibitors (#Q000037)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Middle Aged (#D008875)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Neoplasm Invasiveness (#D009361)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Neoplasm Staging (#D009367)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Probability (#D011336)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prognosis (#D011379)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Survival Analysis (#D016019)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Treatment Outcome (#D016896)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()